Mirapexin®/Sifrol® (pramipexole)

Mirapexin®/Sifrol® (pramipexole):
>five million patient-years of experience in Parkinson's disease

Clinical evidence

  • There is considerable evidence base testifying to the clinical efficacy and tolerability of Mirapexin®/Sifrol® (pramipexole) with over a decade of worldwide experience in the treatment of PD in more than five million patient-years exposure1
    (Patient-years refers to the total number of years that known patients have taken a drug)
  • Mirapexin®/Sifrol® has been shown to successfully manage the symptoms of PD in the longer term beyond four years2,3
    • For more information about Mirapexin®/Sifrol® and the motor symptoms, click here
    • For more information about Mirapexin®/Sifrol® and the non-motor symptoms,
      click here
    • For more information about Mirapexin®/Sifrol® and ongoing research, click here

View references

  1. Pramipexole European SPC. Annex I: Summary of product characteristics. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Sifrol/H-133-PI-en.pdf. Date accessed October 2009.
  2. Möller JC et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20(5): 602-610.
  3. Parkinson Study Group, Holloway RG et al. Pramipexole vs levodopa as initial treatment for Parkinson's disease. Arch Neurol 2004; 61(7): 1044-1053.

Close